Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Raised to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a strong-buy rating in a research note published on Wednesday,Zacks reports.

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $67.67.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $44.68 on Wednesday. The business has a 50 day simple moving average of $50.06 and a 200 day simple moving average of $51.33. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.44 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. During the same quarter in the previous year, the firm posted $0.90 earnings per share. The business’s revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts anticipate that Prestige Consumer Healthcare will post 4.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Prestige Consumer Healthcare during the second quarter worth $370,187,000. Rice Hall James & Associates LLC acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $32,602,000. The Manufacturers Life Insurance Company bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $31,135,000. Norges Bank bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $36,954,000. Finally, Bank of America Corp DE acquired a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at about $26,277,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, markets and distributes over-the-counter (OTC) products and household health-care brands. Its portfolio includes products for eye care, oral care, gastrointestinal health, pain relief, respiratory health, women’s health, and other everyday health needs.

The company’s brands include Dramamine, Bonine, BC, Goody’s, Clear Eyes, TheraTears, Monistat, Summer’s Eve, Vagisil, Luden’s, Chloraseptic, Compound W, Fleet and Debrox.